Patents by Inventor Brian Seed

Brian Seed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180215831
    Abstract: Antibody derivatives that have diminished effector function in the initial state owing to the presence of one or more disabling moieties that substantially prevent engagement of the antibody regions responsible for interaction with humoral and cellular immune system effector molecules, and methods of use thereof.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 2, 2018
    Inventors: Glen S. CHO, Brian SEED
  • Publication number: 20180118773
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 3, 2018
    Inventors: Mengzhuang CAI, Qian LIU, Ge XU, Binhua LV, Brian SEED, Jacques ROBERGE
  • Patent number: 9834573
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: December 5, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: 9725478
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 8, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Roberge
  • Patent number: 9493747
    Abstract: Disclosed herein are methods and compositions related to engineered fragments of the human transglutaminase-related protein family, described herein as engineered transglutaminase barrel proteins (ETBPs), that have utility as high affinity, high selectivity target-binding proteins offering advantages as antibody equivalents for therapeutic, analytical, manufacturing and research purposes. ETBPs differ from naturally occurring human transglutaminase fragments by the addition, deletion, replacement and/or substitution of the naturally occurring amino acid sequence. ETBPs can be easily expressed in prokaryotic cells and in many cases can be purified by a simple solubilization and precipitation method.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: November 15, 2016
    Assignee: The General Hospital Corporation
    Inventors: Elena V. Getmanova, Alexander Kovtun, Lin Sun, Edward Fritsch, Brian Seed
  • Publication number: 20160207952
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 19, 2015
    Publication date: July 21, 2016
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Roberge
  • Patent number: 9340584
    Abstract: The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: May 17, 2016
    Assignee: The General Hospital Corporation
    Inventors: Jia Liu Wolfe, Glen S. Cho, Brian Seed
  • Patent number: 9193751
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: November 24, 2015
    Assignee: Theracos, Inc.
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Y. Roberge
  • Publication number: 20150266915
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: February 20, 2015
    Publication date: September 24, 2015
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: 9061060
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: June 23, 2015
    Assignee: Theracos Inc.
    Inventors: Brian Seed, Binhua Lv, Jacques Y. Roberge, Yuanwei Chen, Kun Peng, Jiajia Dong, Baihua Xu, Jiyan Du, Lili Zhang, Xinxing Tang, Ge Xu, Yan Feng, Min Xu
  • Patent number: 8993295
    Abstract: The present invention provides methods and compositions for treating various diseases through selective killing of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: March 31, 2015
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, Jia Liu Wolfe, Glen S. Cho, Chia-Iun Tsai
  • Patent number: 8987323
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 24, 2015
    Assignee: Theracos, Inc.
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: 8802637
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 12, 2014
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Binhua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Patent number: 8748419
    Abstract: Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: June 10, 2014
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • Patent number: 8735389
    Abstract: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 27, 2014
    Assignee: Theracos, Inc.
    Inventors: Brian Seed, Jordan Mechanic
  • Publication number: 20140113832
    Abstract: The invention features compositions based on thioredoxin-like fold protein domains described as engineered thioredoxin-like fold proteins (ETRXs). These proteins include one or more artificially diversified thioredoxin-like fold protein domains; each domain may be originated from the same or different thioredoxin-like fold protein domains. Features of the invention also include methods for identifying and preparing an enriched composition of target binding, loop-diversified ETRXs with additional sequence variations to improve affinity, stability, selectivity, or solubility. The invention also features compositions of ETRXs substituted with prosthetic groups, polymers, proteins, nucleic acids, carbohydrates, metals, natural or synthetic small molecules and toxins.
    Type: Application
    Filed: March 29, 2012
    Publication date: April 24, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Jia Liu Wolfe, Glen S. Cho, Brian Seed
  • Publication number: 20140031300
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
  • Publication number: 20140011754
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 9, 2014
    Applicant: Theracos, Inc.
    Inventors: Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
  • Patent number: 8575321
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 5, 2013
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Roberge
  • Publication number: 20130267694
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Application
    Filed: May 8, 2013
    Publication date: October 10, 2013
    Applicant: Theracos, Inc.
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Y. Roberge